Personal Finance

Why ImmunoGen Tumbled 20.3% Today

Letters shoot out of a megaphone.

What happened

Investors reined in risk Wednesday ahead of data from a phase 3 trial that could support the eventual approval of one of ImmunoGen Inc. 's (NASDAQ: IMGN) most anticipated drugs and news regarding presentations planned for an upcoming conference. Investors' flight to safety caused shares in ImmunoGen to lose 20.3% of their value

So what

ImmunoGen's mirvetuximab soravtansine is an antibody-drug conjugate (ADC) in late-stage trials for use in patients with platinum-resistant ovarian cancer who have received at least one prior treatment.

Letters shoot out of a megaphone.


There's no set date for when management will release results from this registration-enabling study, but the company did indicate on its earnings conference call earlier this month that results from its Forward I trial would be available by June 30. If the data is good, ImmunoGen plans to file for a U.S. Food and Drug Administration OK and European approval in the second half of 2019.

After the closing bell today, management said it will have 11 posters for other drugs that are in its development pipeline at the American Association of Cancer Research (AACR) Annual Meeting from March 29 to April 3, 2019.

Now what

In hopes of a positive outcome, ImmunoGen's been bulking up cash on its balance sheet to support a potential launch. The company started the year with $325 million on the books following a public offering and the sale of its royalty stream on Kadcyla, an ADC for HER2-positive breast cancer that's licensed to Roche Holdings and that won FDA approval in 2013.

The company spent $166.4 million on its operations in 2018, and it anticipates its current cash stockpile can "fund its operations at least a year beyond the release of top-line results from the phase 3 Forward I trial".

In addition to mirvetuximab soravtansine's monotherapy results, management also expects to have initial results from its Forward II program available this year. Forward II is a triplet combination approach to treating ovarian cancer that includes mirvetuximab soravtansine, carboplatin, and Avastin.

10 stocks we like better than ImmunoGen

When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has quadrupled the market.*

David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and ImmunoGen wasn't one of them! That's right -- they think these 10 stocks are even better buys.

See the 10 stocks

*Stock Advisor returns as of February 1, 2019

Todd Campbell has no position in any of the stocks mentioned. His clients may have positions in the companies mentioned. The Motley Fool recommends ImmunoGen. The Motley Fool has a disclosure policy .

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story


Other Topics


The Motley Fool

Founded in 1993 in Alexandria, VA., by brothers David and Tom Gardner, The Motley Fool is a multimedia financial-services company dedicated to building the world's greatest investment community. Reaching millions of people each month through its website, books, newspaper column, radio show, television appearances, and subscription newsletter services, The Motley Fool champions shareholder values and advocates tirelessly for the individual investor. The company's name was taken from Shakespeare, whose wise fools both instructed and amused, and could speak the truth to the king -- without getting their heads lopped off.

Learn More